CN112472718A - Composition for improving side effect of electrolyte disorder of oral intestinal tract cleaning or preparation agent - Google Patents
Composition for improving side effect of electrolyte disorder of oral intestinal tract cleaning or preparation agent Download PDFInfo
- Publication number
- CN112472718A CN112472718A CN202011391356.4A CN202011391356A CN112472718A CN 112472718 A CN112472718 A CN 112472718A CN 202011391356 A CN202011391356 A CN 202011391356A CN 112472718 A CN112472718 A CN 112472718A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- parts
- agent
- sodium
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 87
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 81
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 239000003792 electrolyte Substances 0.000 title claims abstract description 37
- 230000000694 effects Effects 0.000 title abstract description 19
- 238000004140 cleaning Methods 0.000 title description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 62
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 62
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 62
- 210000004347 intestinal mucosa Anatomy 0.000 claims abstract description 57
- 230000006378 damage Effects 0.000 claims abstract description 51
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 48
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 34
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 33
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 32
- 239000001103 potassium chloride Substances 0.000 claims abstract description 31
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 31
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 31
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 31
- 239000011780 sodium chloride Substances 0.000 claims abstract description 31
- 229910052938 sodium sulfate Inorganic materials 0.000 claims abstract description 26
- 235000011152 sodium sulphate Nutrition 0.000 claims abstract description 26
- 230000004888 barrier function Effects 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 230000035699 permeability Effects 0.000 claims abstract description 17
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 78
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 39
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 39
- 210000004369 blood Anatomy 0.000 claims description 28
- 239000008280 blood Substances 0.000 claims description 28
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 claims description 23
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 claims description 23
- 206010014418 Electrolyte imbalance Diseases 0.000 claims description 20
- 239000011734 sodium Substances 0.000 claims description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
- 210000000936 intestine Anatomy 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 229910001414 potassium ion Inorganic materials 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 229910001415 sodium ion Inorganic materials 0.000 claims description 9
- 239000003599 detergent Substances 0.000 claims description 8
- 230000004675 intestinal mucosal permeability Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 239000012459 cleaning agent Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 3
- 230000036541 health Effects 0.000 abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 238000011084 recovery Methods 0.000 abstract description 4
- 229960003010 sodium sulfate Drugs 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 16
- 210000005027 intestinal barrier Anatomy 0.000 description 13
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000003599 L-arabinosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)CO1)* 0.000 description 4
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000004682 mucosal barrier function Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229940056729 sodium sulfate anhydrous Drugs 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000003911 electrolyte status Effects 0.000 description 2
- -1 etc.) Polymers 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 230000004677 mucosal permeability Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001320 aldopentoses Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-KLVWXMOXSA-N beta-L-arabinopyranose Chemical compound O[C@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KLVWXMOXSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition for ameliorating the side effects of electrolyte disorders in oral bowel cleansing or bowel preparation agents. Specifically, the invention provides a composition which comprises arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate. According to the invention, arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate can be taken orally, so that the side effects of electrolyte disorder, intestinal mucosa permeability increase, intestinal mucosa injury, intestinal mucosa barrier damage and the like caused by the intestinal tract preparation process of the intestinal tract preparation agent or the intestinal tract preparation agent can be effectively improved, the side effects caused by the intestinal tract preparation agent or the intestinal tract preparation agent taken orally are improved, and the health recovery of the intestinal tract preparation of a patient is improved.
Description
Technical Field
The invention relates to the field of medicines, in particular to a composition for improving electrolyte disturbance side effects of an oral intestinal tract cleaning or intestinal tract preparation agent.
Background
Electrolytes are widely distributed inside and outside cells, participate in various important metabolic activities in vivo, and play a very important role in maintaining normal life activities. The disturbance of electrolyte metabolism can cause corresponding obstacles to the physiological functions of all organ systems of the whole body, particularly cardiovascular system and nervous system and the metabolism of the substances of the body, and serious conditions can lead to the death of animals. Potassium ions in serum electrolytes can maintain normal physiological activities of organisms, ensure cell metabolism, and particularly have important physiological effects in the aspects of electrical activity of cardiac muscle cells, normal functions of nerves and muscles, normal acid-base balance maintenance, stable cell osmotic pressure and the like. The most common manifestation of electrolyte disturbance is a decrease in the concentration of potassium and sodium ions in the blood.
Magnesium sulfate is a commonly used effective bowel clearing or preparation agent for use in enteroscopy or bowel surgery. However, magnesium sulfate often causes rapid loss of electrolytes from digestive juices during bowel preparation, while reducing effective absorption of supplemental electrolytes and presenting electrolyte disturbances such as low blood sodium and low blood potassium, which can be detrimental to the health of the patient undergoing bowel preparation. And studies have also shown that intestinal mucosal permeability is often increased, intestinal mucosal damage and barrier disruption during intestinal tract preparation with bowel clearing agents such as magnesium sulfate. Therefore, electrolyte disorder, permeability increase of intestinal mucosa, injury of intestinal mucosa and barrier damage of intestinal mucosa caused by preparation of intestinal tract of the bowel clearing agent seriously affect the psychology of the intestinal tract preparation before enteroscopy detection of patients, greatly reduce the compliance of the patients and have adverse effect on the health recovery of the patients.
Therefore, there is a need in the art to develop a drug for improving side effects such as electrolyte disturbance, increased permeability of intestinal mucosa, damage to intestinal mucosa, and barrier disruption of intestinal mucosa, which are caused during preparation of intestinal tract by a bowel cleansing agent or an intestinal tract preparation agent.
Disclosure of Invention
The invention aims to provide a composition for improving side effects of electrolyte disorder, permeability increase of intestinal mucosa, intestinal mucosa injury, barrier damage of the intestinal mucosa and the like caused by an intestinal tract preparation process of a bowel clearing agent or an intestinal tract preparation agent.
In a first aspect, the present invention provides a composition comprising arabinose, sodium sulphate, sodium chloride, potassium chloride and sodium bicarbonate.
Preferably, the arabinose is L-arabinose.
Preferably, the sodium sulfate is anhydrous sodium sulfate.
Preferably, the arabinose is 200-400 parts by weight, preferably 250-350 parts by weight, more preferably 270-330 parts by weight.
Preferably, the weight part of the sodium sulfate is 40 to 80 parts, preferably 50 to 70 parts, and more preferably 54 to 62 parts.
Preferably, the sodium chloride is present in an amount of 5 to 25 parts by weight, preferably 10 to 20 parts by weight, more preferably 13 to 17 parts by weight.
Preferably, the weight part of the potassium chloride is 2 to 20 parts, preferably 2 to 15 parts, and more preferably 5 to 10 parts.
Preferably, the sodium bicarbonate is present in an amount of 5 to 30 parts by weight, preferably 10 to 20 parts by weight, more preferably 14 to 18 parts by weight.
Preferably, the composition comprises 250-350 parts by weight of arabinose, 50-70 parts by weight of sodium sulfate, 10-20 parts by weight of sodium chloride, 2-15 parts by weight of potassium chloride and 10-20 parts by weight of sodium bicarbonate.
Preferably, the composition comprises 270-330 parts by weight of arabinose, 54-62 parts by weight of sodium sulfate, 13-17 parts by weight of sodium chloride, 5-10 parts by weight of potassium chloride and 14-18 parts by weight of sodium bicarbonate.
Preferably, the composition comprises 290-310 parts by weight of arabinose, 54-58 parts by weight of sodium sulfate, 13-16 parts by weight of sodium chloride, 6-9 parts by weight of potassium chloride and 15-19 parts by weight of sodium bicarbonate.
Preferably, the composition further comprises magnesium sulfate.
Preferably, the weight part of the magnesium sulfate is 400-600 parts, preferably 450-550 parts, more preferably 480-520 parts.
Preferably, the composition is a pharmaceutical composition, a food composition or a health care composition.
Preferably, the composition further comprises a pharmaceutically, food or nutraceutical acceptable carrier.
Preferably, the composition is in a solid or liquid form.
Preferably, the composition is in the form of oral preparation or injection preparation.
Preferably, the composition is in the form of tablets, capsules, oral liquid, granules, powder or syrup.
Preferably, the unit of parts by weight is grams (g).
In a second aspect, the present invention provides the use of a composition according to the first aspect of the invention for the manufacture of a medicament for one or more uses selected from the group consisting of: (i) improving electrolyte disturbance; (ii) reducing diamine oxidase levels; (iii) for the prevention and/or treatment of damage to the intestinal mucosa; (iv) for inhibiting an increase in intestinal mucosal permeability; (v) improving the damage of the intestinal mucosa barrier.
Preferably, the electrolyte disorder comprises an electrolyte disorder caused by an oral bowel cleansing agent or an intestinal tract preparation agent.
Preferably, the electrolytes include electrolytes in blood, plasma or serum.
Preferably, the blood comprises peripheral blood.
Preferably, the electrolyte is selected from the group consisting of: sodium ions, potassium ions, or a combination thereof.
Preferably, the electrolyte disturbance comprises a decrease in the amount or level.
Preferably, the electrolyte disturbance comprises a decrease in the electrolyte content of the blood.
Preferably, the electrolyte disturbance comprises a reduction in the sodium and/or potassium ion content of the blood.
Preferably, the improvement comprises an increase.
Preferably, said ameliorating electrolyte disturbance comprises increasing the sodium and/or potassium ion content of blood.
Preferably, the diamine oxidase level comprises a plasma, serum or whole blood level of diamine oxidase.
Preferably, the prevention and/or treatment of damage to the intestinal mucosa comprises prevention and/or treatment of damage to the intestinal mucosa by inhibiting an increase in permeability of the intestinal mucosa.
Preferably, said improving gut mucosal barrier damage comprises improving gut mucosal barrier by inhibiting increased gut mucosal permeability and/or improving gut mucosal damage.
Preferably, the increase in permeability of the intestinal mucosa comprises an increase in permeability of the intestinal mucosa caused by oral administration of a bowel cleansing agent or a bowel preparation agent.
Preferably, the damage to the intestinal mucosa comprises damage to the intestinal mucosa caused by oral administration of a bowel clearing agent or a bowel preparation agent.
Preferably, the damage to the intestinal mucosal barrier comprises damage to the intestinal mucosal barrier caused by oral administration of a bowel clearing agent or a bowel preparation agent.
Preferably, the bowel clearing or preparation agent comprises magnesium sulfate and/or PEG.
Preferably, the bowel cleansing agent comprises magnesium sulfate and/or PEG.
Preferably, the bowel preparation agent comprises magnesium sulfate and/or PEG.
Preferably, the PEG comprises PEG 4000.
Preferably, said improving the damage of the intestinal mucosal barrier comprises alleviating the damage of the intestinal mucosal barrier and/or restoring the intestinal mucosal barrier.
In a third aspect, the present invention provides the use of arabinose, for the preparation of a composition for one or more of the uses selected from the group consisting of: (i) improving electrolyte disorder caused by oral intestinal cleaning agent or intestinal tract preparation agent; (ii) reducing diamine oxidase levels; (iii) for the prevention and/or treatment of damage to the intestinal mucosa; (iv) for inhibiting an increase in intestinal mucosal permeability; (v) improving the damage of the intestinal mucosa barrier.
Preferably, the arabinose is L-arabinose.
In a fourth aspect, the present invention provides an intestine clearing agent or an intestine preparation agent, wherein the intestine clearing agent or the intestine preparation agent comprises magnesium sulfate, arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate.
Preferably, the arabinose is L-arabinose.
Preferably, the sodium sulfate is anhydrous sodium sulfate.
Preferably, the weight part of the magnesium sulfate is 400-600 parts, preferably 450-550 parts, more preferably 480-520 parts.
Preferably, the bowel clearing agent or the intestinal tract preparation agent comprises 550 parts by weight of magnesium sulfate of 450-.
Preferably, the bowel clearing agent or the intestinal tract preparation agent comprises 480-520 parts by weight of magnesium sulfate, 270-330 parts by weight of arabinose, 54-62 parts by weight of sodium sulfate, 13-17 parts by weight of sodium chloride, 5-10 parts by weight of potassium chloride and 14-18 parts by weight of sodium bicarbonate.
Preferably, the bowel clearing agent or the intestinal tract preparation agent comprises 490-510 parts by weight of magnesium sulfate, 290-310 parts by weight of arabinose, 54-58 parts by weight of sodium sulfate, 13-16 parts by weight of sodium chloride, 6-9 parts by weight of potassium chloride and 15-19 parts by weight of sodium bicarbonate.
Preferably, the dosage form of the bowel clearing agent or the intestinal tract preparation agent is a solid preparation, a liquid preparation or a semisolid preparation.
Preferably, the intestinal tract clearing agent or the intestinal tract preparation agent is in the form of an oral preparation or an injection preparation.
Preferably, the formulation of the intestine clearing agent or the intestinal tract preparation agent is tablets, capsules, oral liquid, granules, powder or syrup.
Preferably, the intestine clearing agent also comprises other pharmaceutically acceptable carriers.
In a fifth aspect, the present invention provides the use of a bowel cleanser or an intestine preparer according to the fourth aspect of the invention, for the manufacture of a medicament for bowel cleansing and/or intestine preparer.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments.
Detailed Description
The invention finds that arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate can effectively improve the side effects of electrolyte disorder, intestinal mucosa permeability increase, intestinal mucosa injury, intestinal mucosa barrier damage and the like caused by the intestinal tract preparation process of an intestinal tract clearing agent or an intestinal tract preparation agent (such as magnesium sulfate) by oral administration, thereby improving the side effects caused by the oral intestinal tract clearing agent or the intestinal tract preparation agent and improving the health recovery of the intestinal tract preparation of a patient.
Term(s) for
As used herein, the terms "comprising," including, "and" containing "are used interchangeably and include not only open-ended definitions, but also semi-closed and closed-ended definitions, and include" consisting of … …, "" consisting essentially of … ….
The following description of the exemplary embodiments of the present application, including various details of the embodiments of the present application to assist in understanding, should be taken as exemplary only. Accordingly, those of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the present application. Also, descriptions of well-known functions and constructions are omitted in the following description for clarity and conciseness.
Composition comprising a metal oxide and a metal oxide
The invention provides a composition which comprises arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate.
Preferably, the arabinose is L-arabinose. L-arabinose (L-arabinosine, C5H10O5) is an aldopentose, also known as L (+) -arabinose.
Preferably, the sodium sulfate is anhydrous sodium sulfate.
Preferably, the arabinose is 200-400 parts by weight, preferably 250-350 parts by weight, more preferably 270-330 parts by weight.
Preferably, the weight part of the sodium sulfate is 40 to 80 parts, preferably 50 to 70 parts, and more preferably 54 to 62 parts.
Preferably, the sodium chloride is present in an amount of 5 to 25 parts by weight, preferably 10 to 20 parts by weight, more preferably 13 to 17 parts by weight.
Preferably, the weight part of the potassium chloride is 2 to 20 parts, preferably 2 to 15 parts, and more preferably 5 to 10 parts.
Preferably, the sodium bicarbonate is present in an amount of 5 to 30 parts by weight, preferably 10 to 20 parts by weight, more preferably 14 to 18 parts by weight.
Typically, the composition comprises 250-350 parts by weight of arabinose, 50-70 parts by weight of sodium sulfate, 10-20 parts by weight of sodium chloride, 2-15 parts by weight of potassium chloride and 10-20 parts by weight of sodium bicarbonate.
Typically, the composition comprises 270-330 parts by weight of arabinose, 54-62 parts by weight of sodium sulfate, 13-17 parts by weight of sodium chloride, 5-10 parts by weight of potassium chloride and 14-18 parts by weight of sodium bicarbonate.
Typically, the composition comprises 290-310 parts by weight of arabinose, 54-58 parts by weight of sodium sulfate, 13-16 parts by weight of sodium chloride, 6-9 parts by weight of potassium chloride and 15-19 parts by weight of sodium bicarbonate.
Preferably, the composition further comprises magnesium sulfate.
Preferably, the weight part of the magnesium sulfate is 400-600 parts, preferably 450-550 parts, more preferably 480-520 parts.
Preferably, the composition is a pharmaceutical composition, a food composition or a health care composition.
Preferably, the composition further comprises a pharmaceutically, food or nutraceutical acceptable carrier.
Preferably, the composition is in a solid or liquid form.
Preferably, the composition is in the form of oral preparation or injection preparation.
Preferably, the composition is in the form of tablets, capsules, oral liquid, granules, powder or syrup.
Typically, the compositions of the present invention are bowel cleansers or bowel preparations.
Preferably, the bowel cleansing or preparation comprises magnesium sulfate, arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate.
Preferably, the weight part of the magnesium sulfate is 400-600 parts, preferably 450-550 parts, more preferably 480-520 parts.
Typically, the bowel clearing agent or the intestinal tract preparation agent comprises 550 parts by weight of magnesium sulfate of 450-.
Typically, the bowel clearing agent or the intestinal tract preparation agent comprises 480-520 parts by weight of magnesium sulfate, 270-330 parts by weight of arabinose, 54-62 parts by weight of sodium sulfate, 13-17 parts by weight of sodium chloride, 5-10 parts by weight of potassium chloride and 14-18 parts by weight of sodium bicarbonate.
Typically, the bowel clearing agent or the intestinal tract preparation agent comprises 490-510 parts by weight of magnesium sulfate, 290-310 parts by weight of arabinose, 54-58 parts by weight of sodium sulfate, 13-16 parts by weight of sodium chloride, 6-9 parts by weight of potassium chloride and 15-19 parts by weight of sodium bicarbonate.
Preferably, the dosage form of the bowel clearing agent or the intestinal tract preparation agent is a solid preparation, a liquid preparation or a semisolid preparation.
Preferably, the intestinal tract clearing agent or the intestinal tract preparation agent is in the form of an oral preparation or an injection preparation.
Preferably, the formulation of the intestine clearing agent or the intestinal tract preparation agent is tablets, capsules, oral liquid, granules, powder or syrup.
As used herein, the term "pharmaceutically, comestibly or nutraceutically acceptable carrier" refers to: one or more compatible solid, semi-solid, liquid or gel fillers suitable for human or animal use and of sufficient purity and sufficiently low toxicity.
It is to be understood that, in the present invention, the carrier is not particularly limited and may be selected from materials commonly used in the art, or prepared by a conventional method, or commercially available. Examples of the pharmaceutically acceptable carrier moiety are cellulose and its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, etc.), polyols (e.g., propylene glycol, glycerin, sorbitol, etc.), emulsifiers (e.g., tween), wetting agents (e.g., sodium laurylsulfate), buffers, chelating agents, thickeners, pH adjusters, transdermal enhancers, colorants, flavors, stabilizers, antioxidants, preservatives, bacteriostats, pyrogen-free water, etc.
Use of
The present invention provides a composition according to the invention for one or more uses selected from the group consisting of: (i) improving electrolyte disturbance; (ii) reducing diamine oxidase levels; (iii) for the prevention and/or treatment of damage to the intestinal mucosa; (iv) for inhibiting an increase in intestinal mucosal permeability; (v) improving the damage of the intestinal mucosa barrier.
The present invention also provides a use of arabinose for one or more uses selected from the group consisting of: (i) improving electrolyte disorder caused by oral intestinal cleaning agent or intestinal tract preparation agent; (ii) reducing diamine oxidase levels; (iii) for the prevention and/or treatment of damage to the intestinal mucosa; (iv) for inhibiting an increase in intestinal mucosal permeability; (v) improving the damage of the intestinal mucosa barrier.
The invention also provides the application of the bowel clearing agent or the intestinal tract preparation agent in preparing the medicines for clearing the bowel and/or preparing the intestinal tract.
Preferably, the electrolyte disorder comprises an electrolyte disorder caused by an oral bowel cleansing agent or an intestinal tract preparation agent.
Preferably, the electrolytes include electrolytes in blood, plasma or serum.
Preferably, the blood comprises peripheral blood.
Preferably, the electrolyte is selected from the group consisting of: sodium ions, potassium ions, or a combination thereof.
Preferably, the electrolyte disturbance comprises a decrease in the amount or level.
Preferably, the electrolyte disturbance comprises a decrease in the electrolyte content of the blood.
Preferably, the electrolyte disturbance comprises a reduction in the sodium and/or potassium ion content of the blood.
Preferably, the improvement comprises an increase.
Preferably, said ameliorating electrolyte disturbance comprises increasing the sodium and/or potassium ion content of blood.
Preferably, the diamine oxidase level comprises a plasma, serum or whole blood level of diamine oxidase.
Preferably, the prevention and/or treatment of damage to the intestinal mucosa comprises prevention and/or treatment of damage to the intestinal mucosa by inhibiting an increase in permeability of the intestinal mucosa.
Preferably, said improving gut mucosal barrier damage comprises improving gut mucosal barrier by inhibiting increased gut mucosal permeability and/or improving gut mucosal damage.
Preferably, the increase in permeability of the intestinal mucosa comprises an increase in permeability of the intestinal mucosa caused by oral administration of a bowel cleansing agent or a bowel preparation agent.
Preferably, the damage to the intestinal mucosa comprises damage to the intestinal mucosa caused by oral administration of a bowel clearing agent or a bowel preparation agent.
Preferably, the damage to the intestinal mucosal barrier comprises damage to the intestinal mucosal barrier caused by oral administration of a bowel clearing agent or a bowel preparation agent.
Preferably, the bowel clearing or preparation agent comprises magnesium sulfate and/or PEG.
Preferably, the bowel cleansing agent comprises magnesium sulfate and/or PEG.
Preferably, the bowel preparation agent comprises magnesium sulfate and/or PEG.
Preferably, the PEG comprises PEG 4000.
Preferably, said improving the damage of the intestinal mucosal barrier comprises alleviating the damage of the intestinal mucosal barrier and/or restoring the intestinal mucosal barrier.
The main technical effects obtained by the invention comprise:
the invention finds that arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate can effectively improve the side effects of electrolyte disorder, intestinal mucosa permeability increase, intestinal mucosa injury, intestinal mucosa barrier damage and the like caused by the intestinal tract preparation process of an intestinal tract clearing agent or an intestinal tract preparation agent (such as magnesium sulfate) by oral administration, thereby improving the side effects caused by the oral intestinal tract clearing agent or the intestinal tract preparation agent and improving the health recovery of the intestinal tract preparation of a patient.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1
This example 1 examines the ameliorating effect of L-arabinose and electrolytes on electrolyte disorders caused by the preparation of magnesium sulfate for the intestinal tract
Laboratory animal
Experimental animals and their rearing: KM mice, Specific Pathogen Free (SPF) grade, male, 6 weeks old; the common feed is D12450-B feed: 67.35 wt% carbohydrate, 19.2 wt% crude protein, 4.3 wt% fat. The temperature of the room is kept at 24-26 ℃ and the humidity is 40-60%.
The experimental method comprises the following steps:
KM mice were randomly divided into a blank control group, experimental group 1, experimental group 2, experimental group 3, experimental group 4, experimental group 5, experimental group 6 and experimental group 7, 40 mice per group, male and female halves.
The mice of each group are fasted and are not forbidden to drink water at 12 pm in the day, and the mice of each group are respectively subjected to intragastric administration as follows at 8 pm;
blank control group: irrigating the stomach with water;
experimental group 1: magnesium sulfate was administered by gavage with water at a dose of 0.5 g/kg.bw;
experimental group 2: gavage with water magnesium sulfate (dose 0.5g/kg.bw) and L-arabinose (dose 0.3 g/kg.bw);
experimental group 3: intragastrically administering magnesium sulfate (dose 0.5g/kg.bw) and an electrolyte powder (dose: anhydrous sodium sulfate (56mg/kg.bw) + sodium chloride (14.6mg/kg.bw) + potassium chloride (7.5mg/kg.bw) + sodium bicarbonate (16.8mg/kg.bw)) with water;
experimental group 4: intragastrically administering magnesium sulfate (dose 0.5g/kg.bw) and L-arabinose electrolyte (dose: L-arabinose (0.1g/kg.bw) + sodium sulfate anhydrous (56mg/kg.bw) + sodium chloride (14.6mg/kg.bw) + potassium chloride (7.5mg/kg.bw) + sodium bicarbonate (16.8 mg/kg.bw));
experimental group 5: intragastrically administering magnesium sulfate (dose 0.5g/kg.bw) and L-arabinose electrolyte (dose: L-arabinose (0.3g/kg.bw) + sodium sulfate anhydrous (56mg/kg.bw) + sodium chloride (14.6mg/kg.bw) + potassium chloride (7.5mg/kg.bw) + sodium bicarbonate (16.8 mg/kg.bw));
experimental group 6: intragastrically administering magnesium sulfate (dose 0.5g/kg.bw) and L-arabinose electrolyte (dose: L-arabinose (1g/kg.bw) + sodium sulfate anhydrous (56mg/kg.bw) + sodium chloride (14.6mg/kg.bw) + potassium chloride (7.5mg/kg.bw) + sodium bicarbonate (16.8 mg/kg.bw));
experimental group 7: magnesium sulfate (dose 0.5g/kg.bw) and L-arabinose electrolyte (dose: L-arabinose (2g/kg.bw) + sodium sulfate anhydrous (56mg/kg.bw) + sodium chloride (14.6mg/kg.bw) + potassium chloride (7.5mg/kg.bw) + sodium bicarbonate (16.8mg/kg.bw)) were administered by gavage with water.
After gavage, the mice in each group continued to fast without water deprivation. At 8 am, each group of mice is administered with gastric lavage again according to the administration mode, after fasting and water-deprivation for 2h, each group of mice is cut off the tail and blood is taken, and blood is obtained by centrifugationCleaning, measuring Na in serum by full-automatic biochemical analyzer+、K+The ion concentration.
Na in serum of blank control group mouse measured by full-automatic biochemical analyzer+The content is 158.47 +/-2.58 mmol/L, and K in serum+The content is 8.01 plus or minus 0.33mmol/L, and the serum Na is measured by a full-automatic biochemical analyzer+The content of less than 143.0mmol/L is defined as low blood sodium, and the serum K is+A content of less than 7.2mmol/L is defined as hypokalemia.
The serum electrolyte status of the mice of different groups is shown in the following table 1:
TABLE 1 serum electrolyte status in different groups of mice
| Group of | Low blood sodium (only) | Hypokalemia (only) |
| Blank control group | 0 | 0 |
| Experimental group 1 | 26 | 27 |
| Experimental group 2 | 29 | 31 |
| Experimental group 3 | 18 | 17 |
| Experimental group 4 | 14 | 13 |
| Experimental group 5 | 7 | 6 |
| Experimental group 6 | 11 | 13 |
| Experimental group 7 | 15 | 16 |
As can be seen from table 1, oral magnesium sulfate bowel cleansing can lead to low blood sodium and low blood potassium side effects, leading to electrolyte disturbances. As can be seen from comparison of experimental groups 1-7, after arabinose, anhydrous sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate with specific proportions are orally taken together with magnesium sulfate, the occurrence probability of electrolyte disturbance of low blood sodium and low blood potassium can be remarkably reduced, and the arabinose, anhydrous sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate with specific proportions can improve the side effect of electrolyte disturbance of low blood sodium and low blood potassium caused by orally taken bowel clearing agent magnesium sulfate.
Serum from each group of low blood sodium mice was assayed for diamine oxidase (DAO) using a spectrophotometer, and the DAO absorbance a value was read at 436 nm.
Serum diamine oxidase (DAO) levels of different groups of low blood sodium mice are shown in table 2:
TABLE 2 serum diamine oxidase (DAO) levels in different groups of mice
Note: p < 0.05, ", P < 0.01 was compared to the blank control group.
Diamine oxidase (DAO), a highly active intracellular enzyme, is present in the mucous membrane or upper villus layer of mammals, and when the permeability is increased due to the damage of the epithelial barrier of the intestinal mucosa, DAO is released into the blood to increase the content of DAO in the peripheral blood, and thus, serum diamine oxidase (DAO) is an indicator of the increase in permeability of the intestinal mucosa, the damage of the intestinal mucosa, and the barrier of the intestinal mucosa. As can be seen from table 2, magnesium sulfate, used as an intestinal tract preparation agent in the gut purge process, was able to disrupt the intestinal mucosal permeability and intestinal mucosal barrier. From the data of experimental groups 2-7, it can be seen that L-arabinose and its combined anhydrous sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate can reduce intestinal mucosa permeability and reduce the damage of oral magnesium sulfate to intestinal mucosa, thereby protecting intestinal mucosa barrier.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (10)
1. A composition comprising arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate.
2. The composition of claim 1, wherein the composition comprises about 350 parts by weight of arabinose, about 50 to about 70 parts by weight of sodium sulfate, about 10 to about 20 parts by weight of sodium chloride, about 2 to about 15 parts by weight of potassium chloride, and about 10 to about 20 parts by weight of sodium bicarbonate.
3. Use of a composition according to claim 1 for the preparation of a medicament for one or more uses selected from the group consisting of: (i) improving electrolyte disturbance; (ii) reducing diamine oxidase levels; (iii) for the prevention and/or treatment of damage to the intestinal mucosa; (iv) for inhibiting an increase in intestinal mucosal permeability; (v) improving the damage of the intestinal mucosa barrier.
4. The use of claim 3, wherein the electrolyte disorder comprises an electrolyte disorder caused by an oral bowel cleansing agent or an intestinal tract preparation agent.
5. The use of claim 3, wherein the electrolyte disturbance comprises a reduction in the level of sodium and/or potassium ions in the blood.
6. The use of claim 3, wherein said amelioration of electrolyte disturbance comprises an increase in the level of sodium and/or potassium ions in the blood.
7. The use of claim 3, wherein said increased permeability of the intestinal mucosa comprises an increase in permeability of the intestinal mucosa resulting from oral administration of a bowel clearing or preparation agent;
the damage of the intestinal mucosa comprises the damage of the intestinal mucosa caused by oral intestinal cleaning agent or intestinal tract preparation agent; and/or
The damage of the intestinal mucosa barrier comprises the damage of the intestinal mucosa barrier caused by oral intestinal cleaning agent or intestinal tract preparation agent.
8. Use of arabinose, characterized in that it is used for the preparation of a composition for one or more of the uses selected from the group consisting of: (i) improving electrolyte disorder caused by oral intestinal cleaning agent or intestinal tract preparation agent; (ii) reducing diamine oxidase levels; (iii) for the prevention and/or treatment of damage to the intestinal mucosa; (iv) for inhibiting an increase in intestinal mucosal permeability; (v) improving the damage of the intestinal mucosa barrier.
9. An intestine clearing agent or an intestine preparation agent, which is characterized by comprising magnesium sulfate, arabinose, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate.
10. Use of a bowel clearing agent or bowel preparation according to claim 9 for the preparation of a medicament for bowel clearing and/or preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011391356.4A CN112472718B (en) | 2020-12-01 | 2020-12-01 | Composition for improving electrolyte disturbance side effect of oral intestine cleaning or intestine preparation agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011391356.4A CN112472718B (en) | 2020-12-01 | 2020-12-01 | Composition for improving electrolyte disturbance side effect of oral intestine cleaning or intestine preparation agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112472718A true CN112472718A (en) | 2021-03-12 |
| CN112472718B CN112472718B (en) | 2023-05-26 |
Family
ID=74938916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011391356.4A Active CN112472718B (en) | 2020-12-01 | 2020-12-01 | Composition for improving electrolyte disturbance side effect of oral intestine cleaning or intestine preparation agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112472718B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112451533A (en) * | 2020-12-03 | 2021-03-09 | 唐传生物科技（厦门）有限公司 | Composition for improving side effect of oral intestinal tract cleaning agent |
| CN116509809A (en) * | 2023-04-19 | 2023-08-01 | 山东齐都药业有限公司 | Compound sodium sulfate tablet and preparation method and application thereof |
| CN118477085A (en) * | 2024-05-16 | 2024-08-13 | 中国人民解放军总医院第七医学中心 | Syrup for preparing intestinal tract and improving electrolyte and intestinal flora disorder caused by intestinal tract preparation and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150021A (en) * | 1996-01-11 | 1997-05-21 | 李智军 | Bowel clearing agent |
| CN102805752A (en) * | 2012-08-20 | 2012-12-05 | 深圳万和制药有限公司 | Compound polyethylene glycol electrolyte powder and preparation method thereof |
| CN112089717A (en) * | 2020-08-25 | 2020-12-18 | 唐传生物科技（厦门）有限公司 | Application of arabinose and composition for preparing intestinal tract |
-
2020
- 2020-12-01 CN CN202011391356.4A patent/CN112472718B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150021A (en) * | 1996-01-11 | 1997-05-21 | 李智军 | Bowel clearing agent |
| CN102805752A (en) * | 2012-08-20 | 2012-12-05 | 深圳万和制药有限公司 | Compound polyethylene glycol electrolyte powder and preparation method thereof |
| CN112089717A (en) * | 2020-08-25 | 2020-12-18 | 唐传生物科技（厦门）有限公司 | Application of arabinose and composition for preparing intestinal tract |
Non-Patent Citations (3)
| Title |
|---|
| 张小红: "肠镜检查前肠道不同准备方法的效果比较", 《护理研究》 * |
| 王昕等: "L-阿拉伯糖在结肠镜检查前肠道准备中的应用", 《中华消化内镜杂志》 * |
| 邓家征等: "小剂量复方聚乙二醇联合硫酸镁用于肠道准备的效果评价", 《临床和实验医学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112451533A (en) * | 2020-12-03 | 2021-03-09 | 唐传生物科技（厦门）有限公司 | Composition for improving side effect of oral intestinal tract cleaning agent |
| CN116509809A (en) * | 2023-04-19 | 2023-08-01 | 山东齐都药业有限公司 | Compound sodium sulfate tablet and preparation method and application thereof |
| CN118477085A (en) * | 2024-05-16 | 2024-08-13 | 中国人民解放军总医院第七医学中心 | Syrup for preparing intestinal tract and improving electrolyte and intestinal flora disorder caused by intestinal tract preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112472718B (en) | 2023-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112472718A (en) | Composition for improving side effect of electrolyte disorder of oral intestinal tract cleaning or preparation agent | |
| US7964581B2 (en) | Use of difructose anhydride-containing composition | |
| JP5498521B2 (en) | Radiation damage reducing agent | |
| WO2003032968A1 (en) | Compositions for lessening oxidative stress | |
| WO2018090983A9 (en) | Saponin compound for improving intestinal microflora, preparation method and use thereof | |
| CN112370470A (en) | Microecological preparation for reconstructing intestinal microecology | |
| US20090220624A1 (en) | Compositions comprising apocynin, ginkgo and ginger and uses thereof | |
| US20080044493A1 (en) | Agent For Ameliorating The Maximum Passage Time Through Digestive Tract, Agent For Ameliorating Passage Time Through Digestive Tract And Preventive For Colon Cancer | |
| CN112168855B (en) | A composition for preparing intestinal tract and treating constipation | |
| Lian et al. | Combination of Artemisia selengensis Turcz leaves polysaccharides and dicaffeoylquinic acids could be a potential inhibitor for hyperuricemia | |
| CN105832759B (en) | A pharmaceutical composition for preventing and/or treating diseases caused by coronavirus and/or rotavirus | |
| US20200261483A1 (en) | Methods and compositions for treating cystic fibrosis | |
| US20180008563A1 (en) | Pharmaceutical composition for preventing and/or treating disease caused by coronavirus and/or rotavirus | |
| CN112451533A (en) | Composition for improving side effect of oral intestinal tract cleaning agent | |
| CN110269853B (en) | Application of galopam in preparation of medicine for resisting coccidiosis | |
| Scadding | Acute iodism following lipiodol bronchography | |
| JP2009298702A (en) | Oral administration composition | |
| CN111467356A (en) | L-arabinose-containing pharmaceutical composition for treating constipation and application method thereof | |
| JP6355806B1 (en) | A therapeutic agent for constipation containing lactulose as an active ingredient | |
| CN115671118B (en) | Application of brown alginate oligosaccharides | |
| CN114617916B (en) | Loquat leaf extract and application thereof in health care | |
| CN114073692B (en) | Composition containing L-carnitine or its derivatives and application thereof | |
| CN108392469A (en) | Application of the Tiopronin in preparing medicament for resisting Eimeria tenella | |
| CN112206236A (en) | Application of L-arabinose in inhibiting intestinal gas production of sorbitol | |
| CN114452352A (en) | Anti-fatigue composition for improving kidney deficiency and essence deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Lin Weijun Inventor after: Shi Guoliang Inventor after: Wang Yujuan Inventor after: Cai Xubin Inventor after: Guo Zhijian Inventor before: Lin Weijun Inventor before: Shi Guoliang Inventor before: Wang Yujuan Inventor before: Cai Xubin Inventor before: Guo Zhijian |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |